India Molecular Diagnostics Market By Application (Infectious Disease, Blood Screening, Genetic Testing, Oncology Testing), By Technology (PCR, In-situ Hybridization, Chips and Microarrays, Mass Spectrometry, Sequencing, Others), By End User (Hospitals, Academic & Reference Laboratories), By Region, Competition, Forecast & Opportunities, 2020-2030F

Market Overview

India Molecular Diagnostics Market was valued at USD 941.24 Million in 2024 and is expected to reach USD 1413.74 Million by 2030, growing at a CAGR of 7.12% during the forecast period.

Molecular Diagnostics encompasses a diverse range of techniques used to analyze biological markers in the genome and proteome. Using these advanced methods, scientists can detect and quantify genetic material associated with specific diseases, enabling accurate disease diagnosis and comprehensive characterization. This invaluable information not only guides potential treatment strategies but also allows for ongoing monitoring of disease progression. With its profound impact, Molecular Diagnostics has emerged as an indispensable component of modern clinical practice, playing a pivotal role in disease detection, staging, and therapy monitoring, thereby revolutionizing healthcare. For instance, in August 2024, Siemens Healthineers received approval to manufacture the IMDX Monkeypox Detection RT-PCR Assay in India. The kit was set to be produced at the company’s molecular diagnostics unit in Vadodara, which had a production capacity of 1 million reactions. This move marked a significant boost to India’s molecular diagnostics market, enhancing local manufacturing capabilities and supporting timely, large-scale mpox detection amid rising public health preparedness efforts.

The Molecular Diagnostics Market is the healthcare sector that focuses on the use of molecular biology technologies for medical testing. This field employs techniques such as polymerase chain reaction (PCR), in situ hybridization, DNA sequencing, and others to analyze biological markers in the genome and proteome. These techniques are used to diagnose and monitor disease, detect risk, and decide which therapies will work best for individual patients. The market encompasses infectious diseases, oncology, genetics, and blood screening tests and is continually growing, driven by technological advancements and the increasing prevalence of infectious diseases and various cancers.

Key Market Drivers

Large Outbreaks of Bacterial and Viral Epidemics

Large outbreaks of bacterial and viral epidemics are significantly increasing the demand for molecular diagnostics in India, as techniques such as polymerase chain reaction tests, nucleic acid amplification tests, and next-generation sequencing enable rapid and accurate identification of infectious pathogens. The ability to quickly confirm the causative agent is critical for outbreak management because it supports targeted treatment, contact tracing, and isolation measures that reduce transmission, especially during highly contagious outbreaks such as COVID-19. For instance, India has scaled public health diagnostic capacity through the Department of Health Research’s Virus Research and Diagnostic Laboratory (VRDL) network, with 165 VRDLs operational across 26 States and 5 Union Territories, and the scheme approved for continuation from 2021-22 to 2025-26, with a target to establish 42 additional VRDLs.

Molecular diagnostics offer higher sensitivity and specificity than many traditional approaches, helping detect pathogens even when viral or bacterial loads are low in early infection and reducing the risk of missed cases. Their versatility also supports multiplexing, allowing multiple pathogens to be screened from a single sample, which is valuable during outbreaks when co-infections or new variants may affect clinical decisions and public health responses. For instance, India’s genomic surveillance capacity has been institutionalized through INSACOG, described as a consortium of 64 laboratories, and its dashboard reports a total of 260,586 SARS-CoV-2 genome sequences uploaded, reflecting sustained demand for sequencing-led monitoring alongside routine molecular testing.

The COVID-19 pandemic underscored the importance of molecular diagnostics in India and accelerated investments in testing infrastructure, laboratory networks, and surveillance systems that can be repurposed for other epidemic-prone diseases. As India continues to face risks from both known and emerging pathogens, demand is likely to remain elevated for scalable, accurate diagnostics, backed by nationwide public systems designed for timely identification of outbreak agents and rapid deployment of resources. For instance, the VRDL programme explicitly positions this network for timely diagnosis and identification of viral and emerging pathogens during outbreaks and epidemics, supported by an approved outlay of Rs. 324 crore for continuation during 2021-22 to 2025-26.

Increasing Demand for Point-of-Care Diagnostics

The increasing demand for point-of-care (POC) diagnostics is driving a concurrent rise in the demand for molecular diagnostics in India. POC diagnostics provide rapid, convenient testing at or near the patient's location, and molecular diagnostics play a vital role in meeting this demand for quick, accurate results. One of the key drivers of this trend is the need for timely diagnosis, especially in remote or underserved areas where access to centralized laboratory facilities can be limited. Molecular diagnostics, such as nucleic acid amplification tests (NAATs), enable healthcare providers to detect and identify infectious pathogens with high accuracy, even in resource-constrained settings. This capability is critical during outbreaks or pandemics, as it allows for early detection and containment.

The growing awareness of infectious diseases and the importance of rapid testing, particularly during the COVID-19 pandemic, has led to increased demand for POC molecular diagnostics. Patients and healthcare providers alike seek the convenience and quick turnaround times offered by these technologies. Molecular POC tests are also used to monitor chronic diseases, such as HIV and hepatitis, where regular testing and immediate results are essential for disease management. These tests empower patients to take a more active role in their healthcare and reduce the burden on healthcare systems by reducing the need for multiple clinic visits. For instance, in June 2024, India’s TB diagnostics technology, Truenat, developed by Goa-based Molbio, earned international acclaim at the World Health Assembly. First launched in 2017, Truenat is a portable, battery-powered point-of-care molecular diagnostics device that can be deployed in labs, health centers, and remote field settings. Its recognition highlighted India’s innovation in molecular diagnostics and underscored the country’s contributions to improving global tuberculosis detection and disease management through accessible, high-impact healthcare solutions.

The Indian government has recognized the importance of POC diagnostics and has launched various programs to improve their availability and accessibility nationwide. This includes efforts to promote indigenous manufacturing of POC devices and to integrate them into the healthcare infrastructure. As the demand for POC diagnostics continues to grow in India, molecular diagnostics will remain an integral component of this trend. Their ability to provide rapid, accurate, and on-the-spot results will be essential in addressing the evolving healthcare needs of the Indian population, especially in remote and resource-limited regions.

Rapidly Evolving Technologies

Rapidly evolving molecular diagnostic technologies are significantly increasing demand for these advanced methods in India. Molecular diagnostics, which encompass techniques like polymerase chain reaction (PCR), nucleic acid amplification tests (NAATs), and next-generation sequencing (NGS), have become indispensable tools in healthcare due to their precision, speed, and versatility. As technology continues to advance, turnaround times for molecular tests have significantly shortened, enabling quicker diagnosis and treatment decisions. This speed is crucial in managing infectious diseases, such as COVID-19, as it enables swift contact tracing and isolation measures to curb the spread of the disease.

The versatility of molecular diagnostics plays a pivotal role in their growing demand. These technologies can be applied to a wide range of medical purposes, including infectious disease diagnosis, cancer screening, genetic testing, and monitoring of chronic conditions. As healthcare providers and patients recognize the utility of molecular diagnostics across various medical disciplines, the demand for these tests continues to rise.

Advancements in automation and miniaturization have made molecular diagnostic devices more accessible and user-friendly. This has facilitated their adoption not only in large hospitals but also in smaller healthcare facilities, clinics, and even at the point of care. As a result, a broader range of patients in India can benefit from the precision and reliability of molecular diagnostics. The Indian government, recognizing the importance of molecular diagnostics, has also initiated efforts to enhance their accessibility and affordability. The integration of molecular testing into public health programs and the support for indigenous manufacturing of diagnostic devices contribute to the growing demand for these technologies.

Recent Advancements in Pharmacogenomics

Recent advances in pharmacogenomics are driving increased demand for molecular diagnostics in India. Pharmacogenomics is the study of how an individual's genetic makeup influences their response to drugs, and it holds significant promise in personalizing medicine for patients. Several factors are contributing to the growing demand for molecular diagnostics driven by pharmacogenomics in India. Genetic variations can significantly impact an individual's response to medications, influencing their efficacy and safety. As more people recognize that pharmacogenomic testing can help tailor drug treatments to their specific genetic profiles, demand for these tests is rising.

The availability of affordable and accessible genetic testing technologies has expanded in India. Advances in next-generation sequencing (NGS) and other molecular techniques have made it easier and more affordable to conduct comprehensive genetic testing, including pharmacogenomic assessments. This has paved the way for pharmacogenomic testing to become a routine part of clinical practice. Pharmacogenomics is especially valuable in optimizing drug therapies for conditions like cardiovascular disease, cancer, and psychiatric disorders, which have a significant prevalence in India. Tailoring drug regimens based on an individual's genetic makeup can enhance treatment outcomes, reduce adverse reactions, and improve patient adherence.

The pharmaceutical industry in India is also recognizing the potential of pharmacogenomics in drug development. Incorporating genetic insights into drug discovery and clinical trials can lead to more efficacious and safer medications, further fueling the demand for molecular diagnostics. Recent advancements in pharmacogenomics are driving a growing demand for molecular diagnostics in India. As personalized medicine becomes increasingly integral to healthcare, genetic testing and molecular diagnostics will play a central role in optimizing drug treatments, improving patient outcomes, and reducing healthcare costs in the country.

Download Free Sample Report

Key Market Challenges

Limited Budgets for R&D and Economic Slowdown

Limited budgets for research and development (R&D) combined with economic slowdown are indeed impacting the demand for molecular diagnostics in India. While molecular diagnostics have proven invaluable in healthcare, the country's economic challenges can hinder their widespread adoption. One of the primary factors contributing to the decline in demand for molecular diagnostics is the constrained budgets allocated to R&D in the healthcare sector. Research and development are essential for the innovation and advancement of diagnostic technologies. Limited funding for R&D can hinder the development of new diagnostic tests, improvements in existing tests, and the validation of novel applications. This can slow the pace of technological innovation and limit the introduction of cost-effective, accessible molecular diagnostics. The economic slowdown in India, particularly in recent years, has put financial pressure on both healthcare institutions and individuals. Healthcare budgets have been strained, leading to reduced investments in advanced diagnostic technologies. Individuals may be less inclined to seek expensive molecular diagnostic tests due to financial constraints, especially when alternative, less costly diagnostic options are available.

The high initial capital expenditure required for setting up molecular diagnostic laboratories and the ongoing operational costs can be challenging for healthcare facilities, particularly in resource-constrained areas. This further contributes to the limited accessibility of molecular diagnostics. To address these challenges and stimulate demand for molecular diagnostics in India, there is a need for strategic investments in R&D, healthcare infrastructure, and affordable diagnostic solutions. Government initiatives, public-private partnerships, and innovative financing models can help overcome economic hurdles and facilitate broader access to molecular diagnostics. By mitigating these financial barriers, India can harness the full potential of molecular diagnostics in improving patient care and disease management.

Need for High-complexity Testing Centers

The need for high-complexity testing centers is one factor reducing demand for molecular diagnostics in India. Molecular diagnostics, including techniques like polymerase chain reaction (PCR) and next-generation sequencing (NGS), often require specialized laboratories equipped with advanced instrumentation and highly trained personnel to conduct complex genetic and molecular analyses. However, in many parts of India, there is a shortage of such high-complexity testing centers. Building and operating high-complexity testing centers require significant investments in terms of equipment, facilities, and ongoing maintenance. Many healthcare facilities, especially those in rural and underserved areas, may lack the financial means to establish and sustain them, limiting access to molecular diagnostics for a large portion of the population. The shortage of skilled personnel with expertise in molecular diagnostics poses a significant challenge. Running these complex tests effectively and interpreting the results correctly demand a high level of technical proficiency. India faces a shortage of trained molecular biologists, geneticists, and laboratory technicians capable of conducting these tests accurately, creating a bottleneck to expanding molecular diagnostics services.

The need to centralize high-complexity testing also reduces demand. Patients and healthcare providers often have to send samples to centralized testing centers in major cities, which delays diagnosis and treatment decisions, especially for those in remote areas. This logistical challenge can discourage patients from pursuing molecular diagnostics and limit the efficiency of healthcare systems. To address these issues and increase the demand for molecular diagnostics in India, there is a need for strategic investments in infrastructure, training programs, and decentralization of testing services. By expanding access to high-complexity testing centers and building a skilled workforce, India can better harness the potential of molecular diagnostics to improve healthcare outcomes nationwide.

Key Market Trends

Rapid Technological Advancements

Rapid technological advancements, characterized by accuracy, portability, and cost-effectiveness, are expected to significantly impact India's molecular diagnostics market. As companies strive to stay ahead in this competitive landscape, they continually upgrade their products by implementing new techniques that deliver specific, precise results.

Notably, industry leaders such as Sigma-Aldrich Corporation and QIAGEN are at the forefront of developing a new range of molecular diagnostic techniques. These include innovative methods such as Transcription-Mediated Amplification (TMA) and Loop-Mediated Isothermal Amplification (LAMP), which are proving instrumental in diagnosing various tumors. The growing use of multiplex PCR technologies and real-time PCR equipment, such as QIAGEN's EpiTect Methyl II PCR for detecting DNA methylation, is expected to further propel the market during the forecast period.

With such advancements and continuous innovation, the molecular diagnostics market in India is poised for significant growth, offering improved diagnostic capabilities and contributing to the overall advancement of healthcare in the country.

Rising Geriatric Population

The geriatric population in India is not only rapidly increasing, but it is also expected to rise by 41% over the next decade, according to the Government of India National Statistical Office. This projection indicates that India's geriatric population, aged 60 and above, will reach a staggering 194 million in 2031, compared to 138 million in 2021. Among states, Kerala has the highest share of elderly people, at approximately 16.5%, followed by Tamil Nadu, Himachal Pradesh, Bihar, Uttar Pradesh, and Assam.

Aging has become a significant risk factor for various diseases, such as obesity and diabetes, which, in turn, substantially increase the vulnerability to infectious diseases. For instance, the geriatric population is more susceptible to infectious diseases like COVID-19 due to factors such as decreased immune function, multimorbidity, and physiological changes associated with aging. Alarming statistics from the World Health Organization (WHO) indicate that, until April 2020, approximately 95% of COVID-19-related deaths were reported among patients aged 60 years or above. More than 50% of deaths occurred in patients aged 80 years or older. These figures underscore the urgent need to address the challenges posed by the growing aging population, which is driving the demand for diagnostics and significantly influencing the market's growth.

Segmental Insights

Technology Insights

In 2024, the PCR technology segment emerged as the leader in revenue share. The technology markets for In Situ Hybridization (ISH) and genetic sequencing are expected to experience a surge in demand over the forecast period, driven by several factors. ISH's market share is projected to grow at a compound annual growth rate (CAGR) of over 31% over the forecast period, driven by the rising number of individuals affected by cancer and the increasing need for early diagnosis.

During the COVID-19 pandemic, PCR diagnostics experienced significant demand, primarily due to collaborative efforts by public-private partnerships such as InDx. This initiative aimed to tap into the market's untapped potential by lowering the cost of RT-PCR testing, making it more accessible for widespread population testing. By supporting the rapid indigenous production of RT-PCR diagnostic test kits, this initiative enabled the manufacturing of over 1 million test kits per day. As a result of this remarkable undertaking, the cost of RT-PCR tests fell from USD 10 to USD 7 over just one year. These developments highlight significant advances and efforts in molecular diagnostics, particularly in PCR technology and its applications in critical situations such as the COVID-19 pandemic. The ongoing progress and innovation in this domain are expected to shape the future of diagnostic testing and profoundly impact healthcare outcomes worldwide.

Application Insights

Based on application, the infectious disease segment has emerged as the dominant force in the market, accounting for a significant share of revenue in 2024. Molecular diagnostics, serving as the cornerstone of medical diagnosis for viral, bacterial, and parasitic infections, play a crucial role in this arena. Notably, demand for respiratory infection molecular diagnostics has surged exponentially following the widespread transmission of SARS-CoV-2.

The market is being propelled by the increasing number of product launches within the infectious disease segment. A case in point is BD's April 2020 announcement of the launch of the SARS-CoV-2 test on its BD MAX System. With heightened automation capabilities and the ability to process a larger volume of samples, the demand for molecular diagnostic reagents and consumables is poised to soar, thereby bolstering the overall market growth. Meanwhile, oncology accounts for a significant share of the applications segment, driven by the rising incidence of cancer. The field of oncology research and cancer drug discovery has witnessed remarkable advances in molecular diagnostics using specific biomarkers associated with major cancer-causing genes and their manifestations. The early identification of predictive biomarkers in molecular diagnostics not only enables early detection of cancer in affected patients but also facilitates the development of personalized medications tailored to their specific needs.

Download Free Sample Report

Regional Insights

The western region of India, particularly Maharashtra and Gujarat, is rapidly emerging as a major force in the Molecular Diagnostics Market. This dominance can be attributed to several factors that contribute to its success. The region boasts a robust, state-of-the-art healthcare infrastructure equipped with advanced diagnostic facilities, which facilitates the widespread adoption of molecular diagnostics. This infrastructure ensures that individuals have access to accurate and timely diagnostic services, further enhancing patient care.

There is a high level of awareness among healthcare professionals and the general population in the region about the benefits and applications of molecular diagnostics. Through extensive education and training programs, healthcare providers are well informed about the potential of molecular diagnostics for disease diagnosis, prognosis, and personalized treatment. The general population is increasingly recognizing the value of molecular diagnostics for early disease detection, leading to improved health outcomes.

The western region of India is home to many key market players in molecular diagnostics. This concentration of expertise and resources fosters collaborations and partnerships, facilitating the development and advancement of diagnostic technologies. The continuous exchange of knowledge and ideas among these market players propels the field forward, leading to innovative solutions and improved patient care. Overall, the western region of India continues to shape and reshape the landscape of molecular diagnostics. With its robust healthcare infrastructure, high level of awareness, and concentration of market players, the region remains at the forefront of advancements in diagnostic technologies. By leveraging these strengths, the western region of India is paving the way for the future of molecular diagnostics and improving patient care.

Recent Developments

• In Aug 2025, Avacta confirmed the completion of the sale of Coris BioConcept SRL to 3B BlackBio Dx Ltd, with the closing completed on Aug 29, 2025.
• In Jul 2025, in India-origin molecular diagnostics player 3B BlackBio Dx / TRUPCR Europe announced the acquisition of Belgium-based rapid diagnostics company Coris BioConcept, aiming to combine TRUPCR’s PCR assays with Coris’s rapid test portfolio.
• In Apr 2025 in Molbio’s Truenat HPV‑HR Plus was positioned as a chip-based RT‑PCR test detecting eight high-risk HPV genotypes, explicitly including regionally prevalent types such as HPV 52 and 58.
• In November 2024, Molbio Diagnostics invested $30 million in OptraSCAN to support the expansion of digital pathology in India. The partnership aimed to advance AI-driven diagnostic solutions and enhance healthcare access, particularly in underserved regions. This strategic move strengthened India’s molecular diagnostics market by integrating cutting-edge technologies and fostering innovation, with a focus on global scalability and improving diagnostic accuracy across broader healthcare networks.
• In August 2024, Cambrian Bioworks raised $1.45 million in seed funding to revolutionize molecular diagnostics in India. The funding aimed to accelerate the development of innovative, affordable, and accessible diagnostic solutions tailored to the Indian healthcare landscape. This milestone marked a significant step toward strengthening India’s molecular diagnostics market by supporting homegrown biotech innovation and addressing critical gaps in early disease detection and patient care across diverse population segments.
• In August 2024, India developed an indigenous RT-PCR kit for mpox detection, marking a significant advancement in the country's molecular diagnostics capabilities. The locally manufactured kit aimed to ensure rapid, accurate, and cost-effective diagnosis, reducing reliance on imported testing solutions. This development strengthened India’s preparedness for emerging infectious diseases and highlighted the nation’s growing self-reliance and innovation in the molecular diagnostics market.
• In January 2022, Mylab Discovery Solutions Pvt. Ltd. introduced the CoviSwift, a Point-of-Care (PoC) testing solution for COVID-19. This groundbreaking advancement is projected to increase testing capacity from 3,000 to 60,000 labs in India.

Key Market Players

• Roche Diagnostics India Pvt Ltd
• Abbott India Ltd
• Qiagen India Pvt Ltd
• BioMérieux India Pvt Ltd
• Becton Dickinson Pvt Ltd
• Bio-Techne India Pvt Ltd
• Danaher India (DHR Holding India Pvt. Ltd.)
• Bio-Rad laboratories India Pvt.Ltd

Report Scope:

In this report, the India Molecular Diagnostics Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

• India Molecular Diagnostics Market, By Application:

o   Infectious Disease

o   Blood Screening

o   Genetic Testing

o   Oncology Testing

• India Molecular Diagnostics Market, By Technology:

o   PCR

o   In-situ Hybridization

o   Chips and Microarrays

o   Mass Spectrometry

o   Sequencing

o   Others

• India Molecular Diagnostics Market, By End User:

o   Hospitals

o   Academic & Reference Laboratories

• India Molecular Diagnostics Market, By Region:

o   North

o   South

o   West

o   East

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the India Molecular Diagnostics Market.

Available Customizations:

India Molecular Diagnostics Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

• Detailed analysis and profiling of additional market players (up to five).

India Molecular Diagnostics Market is an upcoming report to be released soon. If you wish an early delivery of this report or want to confirm the date of release, please contact us at [email protected]